JPRN-jRCTs041210023
Recruiting
Phase 2
A phase II study of treatment with neoadjuvant docetaxel, oxaliplatin plus S-1 for advanced esophageal cancer
Kodera Yasuhiro0 sites45 target enrollmentMay 21, 2021
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Kodera Yasuhiro
- Enrollment
- 45
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\) Clinical stage II/III/IVa thoracic esophageal cancer
- •2\) Histologically confirmed squamous cell carcinoma, adenosquamous cell carcinoma or basaloid\-squamous cell carcinoma
- •3\) Clinical T1\-3
- •4\) Ages between 20 years and 79 years
- •5\) Performance status (PS) 0\-1
- •6\) Adequate function of vital organs, including bone marrow, liver, and kidney
- •7\) Written informed consent
Exclusion Criteria
- •1\) History (within 3 years) of malignancies
- •2\) Active infectious disease
- •3\) Psychiatric disease
- •4\) Continuous systemic steroid therapy
- •5\) Allergy of docetaxel, oxaliplatin or S\-1
- •6\) Persistent intestinal bleeding
- •7\) Ineligible for the study at the physician's assessment
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
A Multicenter Phase II Study of Neoadjuvant Docetaxel, Cisplatin and Capecitabine and Protocolized Surgery in Resectable Gastric Cancer An IKZ-based phase II feasibility studygastric cancergastric carcinoma100179901001799110017998NL-OMON31603Jeroen Bosch Ziekenhuis50
Active, Not Recruiting
N/A
A Multicenter Phase II Study of Neoadjuvant Docetaxel, Cisplatin and Capecitabine combined with Protocolized Surgery in Resectable Gastric Cancer - DoCCSEUCTR2007-007273-23-NLJeroen Bosch Hospital
Active, Not Recruiting
N/A
Et fase II forsøg af neoadjuverende behandling med pegyleret liposomal doxorubicin (Caelyx®) og cyklofosfamid +/- trastuzumab med efterfølgende docetaxel til patienter med primær inoperabel og lokoregional avanceret cancer mammae (LABC). - Et videnskabeligt forsøg med kombinations kemoterapi før operation til patienter med brystkræft.EUCTR2008-007951-29-DKHerlev Hospital, Onkologisk Afd. R
Active, Not Recruiting
Phase 1
Clinical trial for the evaluation of a new drug (cabozantinib) treatment given before having kidney surgery in patients with kidney cancer that is advanced or has spreadocally Advanced or Metastatic Renal Cell CarcinomaMedDRA version: 20.0Level: PTClassification code 10050513Term: Metastatic renal cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2018-001201-93-ESFundación ONCOSUR50
Active, Not Recruiting
N/A
Phase II trial assessing neoadjuvant therapy with FEC 100 followed by Taxotere® (docetaxel) plus Vectibix® (panitumumab) in patients with operable, HR and Her-2 negative breast cancer. TVA study. - TVA studyRH- and Her2- operable breast cancer, in neoadjuvant situationMedDRA version: 9.1Level: LLTClassification code 10022882Term: Invasive ductal breast cancerEUCTR2009-012853-39-FRCentre Jean Perrin